Ray Dalio's CC Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 269,611 shares of The Chemours Company (CC) worth $4.27 M, representing 0.02% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in CC, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 269,611 shares. Largest reduction occurred in Q2 2024, reducing 136,461 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's The Chemours Company (CC) Holding Value Over Time
Track share changes against reported price movement
Quarterly The Chemours Company (CC) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2020 | +16,406 | New Buy | 16,406 | $20.91 |
| Q4 2020 | +3,871 | Add 23.60% | 20,277 | $24.81 |
| Q1 2021 | -20,277 | Sold Out | 0 | $0.00 |
| Q1 2022 | +34,393 | New Buy | 34,393 | $31.49 |
| Q2 2022 | -34,393 | Sold Out | 0 | $0.00 |
| Q4 2022 | +119,299 | New Buy | 119,299 | $30.62 |
| Q1 2023 | -56,951 | Reduce 47.74% | 62,348 | $29.94 |
| Q2 2023 | +7,131 | Add 11.44% | 69,479 | $36.89 |
| Q3 2023 | +189,456 | Add 272.68% | 258,935 | $28.05 |
| Q4 2023 | -80,216 | Reduce 30.98% | 178,719 | $31.54 |
| Q1 2024 | +61,396 | Add 34.35% | 240,115 | $26.26 |
| Q2 2024 | -136,461 | Reduce 56.83% | 103,654 | $22.57 |
| Q3 2024 | -103,654 | Sold Out | 0 | $0.00 |
| Q3 2025 | +269,611 | New Buy | 269,611 | $15.84 |
Ray Dalio's The Chemours Company Investment FAQs
Ray Dalio first purchased The Chemours Company (CC) in Q3 2020, acquiring 16,406 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held The Chemours Company (CC) for 14 quarters since Q3 2020.
Ray Dalio's largest addition to The Chemours Company (CC) was in Q3 2025, adding 269,611 shares worth $4.27 M.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 269,611 shares of The Chemours Company (CC), valued at approximately $4.27 M.
As of the Q3 2025 filing, The Chemours Company (CC) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in The Chemours Company (CC) was 269,611 shares, as reported at the end of Q3 2025.